Published in Blood on September 19, 2008
Venous thromboembolic disease. J Natl Compr Canc Netw (2011) 0.93
Deficiencies of proteins C, S and antithrombin and activated protein C resistance--their involvement in the occurrence of Arterial thromboses. J Med Life (2011) 0.84
The association of active cancer with venous thromboembolism location: a population-based study. Mayo Clin Proc (2011) 0.81
Anticoagulants in portal vein thrombosis: don't be so shy! Blood (2009) 0.80
JAK2V617F: Is It Sufficient as a Single Player in Splanchnic Venous Thrombosis? Case Rep Hematol (2015) 0.75
[Sinus thrombosis and idiopathic intracerebral hypertension : Thrombophilia and hormonal influence as potentially relevant causal connections]. Ophthalmologe (2015) 0.75
The coagulopathy of chronic liver disease. N Engl J Med (2011) 5.63
Exposure to particulate air pollution and risk of deep vein thrombosis. Arch Intern Med (2008) 3.96
Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology (2006) 2.72
Prophylaxis of venous thromboembolism in elderly patients with multimorbidity. Intern Emerg Med (2013) 2.64
Embryo implantation after assisted reproductive procedures and maternal thrombophilia. Haematologica (2003) 2.38
NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity (Silver Spring) (2008) 2.23
Living near major traffic roads and risk of deep vein thrombosis. Circulation (2009) 1.98
The international normalized ratio calibrated for cirrhosis (INR(liver)) normalizes prothrombin time results for model for end-stage liver disease calculation. Hepatology (2007) 1.86
von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Blood (2002) 1.85
Risk of venous thromboembolism after air travel: interaction with thrombophilia and oral contraceptives. Arch Intern Med (2003) 1.75
Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities. Circulation (2004) 1.73
Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood (2004) 1.67
Abnormalities of hemostasis in chronic liver disease: reappraisal of their clinical significance and need for clinical and laboratory research. J Hepatol (2007) 1.67
Venous and arterial thrombosis: different sides of the same coin? Eur J Intern Med (2008) 1.65
Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol (2005) 1.63
Adverse reactions in blood and apheresis donors: experience from two Italian transfusion centres. Blood Transfus (2009) 1.62
Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thromb Haemost (2002) 1.62
New antiplatelet agents: why they are needed. Eur J Intern Med (2009) 1.58
Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. Blood (2012) 1.58
Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood (2003) 1.57
Cancers in patients with hemophilia: a retrospective study from the Italian Association of Hemophilia Centers. J Thromb Haemost (2012) 1.57
Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment. Haematologica (2003) 1.56
Efficacy of Helicobacter pylori eradication in raising platelet count in adult patients with idiopathic thrombocytopenic purpura. Haematologica (2002) 1.54
An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology (2009) 1.54
A new era for anticoagulants. Eur J Intern Med (2009) 1.53
Abnormalities of hemostasis and bleeding in chronic liver disease: the paradigm is challenged. Intern Emerg Med (2009) 1.53
Air pollution, smoking, and plasma homocysteine. Environ Health Perspect (2006) 1.53
Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study. Eur J Clin Pharmacol (2011) 1.50
Mesenchymal stem cells for bone, cartilage, tendon and skeletal muscle repair. Bone (2006) 1.50
Quality and reliability of routine coagulation testing: can we trust that sample? Blood Coagul Fibrinolysis (2006) 1.50
Effects on health of air pollution: a narrative review. Intern Emerg Med (2015) 1.48
The syndrome of the "obsessive-compulsory scientist": a new mental disorder? Clin Chem Lab Med (2013) 1.47
Prognostic value of estimated glomerular filtration rate in hospitalized elderly patients. Intern Emerg Med (2013) 1.44
Together we care: new challenges for global haemophilia treatment centers. Indian J Med Res (2009) 1.44
Recombinant human erythropoietin facilitates autologous blood collections in children undergoing corrective spinal surgery. Transfusion (2004) 1.42
Routine coagulation tests in newborn and young infants. J Thromb Thrombolysis (2007) 1.42
Phlebotomy issues and quality improvement in results of laboratory testing. Clin Lab (2006) 1.41
ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica (2008) 1.41
Simultaneous genotyping of coagulation factor XI type II and type III mutations by multiplex real-time polymerase chain reaction to determine their prevalence in healthy and factor XI-deficient Italians. Haematologica (2008) 1.41
Internal and geriatric medicine: an alliance for the challenges of the elderly. Eur J Intern Med (2012) 1.40
CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. Clin Pharmacol Ther (2004) 1.40
The hemostatic balance revisited through the lessons of mankind evolution. Intern Emerg Med (2008) 1.39
Clinical and laboratory patterns of the haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura in southern Iran. Intern Emerg Med (2006) 1.39
Mental depression and cardiovascular disease: a multifaceted, bidirectional association. Semin Thromb Hemost (2009) 1.39
The growing impact of publications in haemostasis and thrombosis journals. Thromb Haemost (2007) 1.38
Global coagulation in myeloproliferative neoplasms. Ann Hematol (2013) 1.38
The stigma of low opioid prescription in the hospitalized multimorbid elderly in Italy. Intern Emerg Med (2014) 1.38
The paradoxical relationship between serum uric acid and cardiovascular disease. Clin Chim Acta (2008) 1.33
von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura. Br J Haematol (2004) 1.31
ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood (2005) 1.27
The role of ethnicity, age and gender in venous thromboembolism. J Thromb Thrombolysis (2010) 1.24
The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding. Thromb Haemost (2002) 1.23
Prophylaxis in people with haemophilia. Thromb Haemost (2009) 1.19
Clinical usefulness of measuring red blood cell distribution width on admission in patients with acute coronary syndromes. Clin Chem Lab Med (2009) 1.19
Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology (2005) 1.17
An unusual case of a spurious, transfusion-acquired haemoglobin S. Blood Transfus (2010) 1.16
Arterial thrombus formation in cardiovascular disease. Nat Rev Cardiol (2011) 1.15
Non-O blood type is the commonest genetic risk factor for VTE: results from a meta-analysis of the literature. Semin Thromb Hemost (2012) 1.15
Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study. Br J Haematol (2005) 1.14
Haemorrhage and amyloidosis. Br J Haematol (2012) 1.14
Acquired haemophilia A: a 2013 update. Thromb Haemost (2013) 1.13
Hemophilia A in the third millennium. Blood Rev (2013) 1.13
Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol (2008) 1.12
Increased mean platelet volume in patients with acute coronary syndromes. Arch Pathol Lab Med (2009) 1.11
Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology (2006) 1.11
Doping in competition or doping in sport? Br Med Bull (2008) 1.11
Molecular defects in type 3 von Willebrand disease: updated results from 40 multiethnic patients. Blood Cells Mol Dis (2003) 1.11
Thrombotic risk factors: basic pathophysiology. Crit Care Med (2010) 1.10
Influence of a light meal on routine haematological tests. Blood Transfus (2010) 1.10
Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome. Haematologica (2003) 1.09
Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice. Br J Clin Pharmacol (2011) 1.09
Imatinib and regression of type 2 diabetes. N Engl J Med (2005) 1.09
N-terminal pro-brain natriuretic peptide on admission has prognostic value across the whole spectrum of acute coronary syndromes. Circulation (2004) 1.08
Laboratory diagnosis of lupus anticoagulants for patients on oral anticoagulant treatment. Performance of dilute Russell viper venom test and silica clotting time in comparison with Staclot LA. Thromb Haemost (2002) 1.08
Past, present and future of hemophilia: a narrative review. Orphanet J Rare Dis (2012) 1.07
Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method. Hepatology (2010) 1.07
Evidence that low protein C contributes to the procoagulant imbalance in cirrhosis. J Hepatol (2013) 1.06
The role of anti-core antibody response in the detection of occult hepatitis B virus infection. Clin Chem Lab Med (2010) 1.06
Moderate red wine consumption and cardiovascular disease risk: beyond the "French paradox". Semin Thromb Hemost (2010) 1.05
A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/ Humate -P: history and clinical performance. Eur J Haematol Suppl (2008) 1.04
The management of hemophilia in elderly patients. Clin Interv Aging (2007) 1.04
A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism. Blood (2004) 1.04
Biochemistry, physiology, and complications of blood doping: facts and speculation. Crit Rev Clin Lab Sci (2006) 1.03
Thrombogenicity and cardiovascular effects of ambient air pollution. Blood (2011) 1.02
How to write a scientific manuscript for publication. Blood Transfus (2012) 1.02
Von Willebrand disease-associated angiodysplasia: a few answers, still many questions. Br J Haematol (2013) 1.01
Help me, Doctor! My D-dimer is raised. Ann Med (2008) 1.01
Mesenchymal stem cells: from biology to clinical use. Blood Transfus (2007) 1.00
Thrombotic complications of erythropoiesis-stimulating agents. Semin Thromb Hemost (2010) 1.00
Hypercoagulability in patients with type 2 diabetes mellitus detected by a thrombin generation assay. J Thromb Thrombolysis (2011) 0.99
Influenza and cardiovascular disease: does swine-origin, 2009 H1N1 flu virus represent a risk factor, an acute trigger, or both? Semin Thromb Hemost (2010) 0.99
Hypercoagulability in splenectomized thalassemic patients detected by whole-blood thromboelastometry, but not by thrombin generation in platelet-poor plasma. Haematologica (2009) 0.99
Air pollution and cardiovascular disease. Thromb Res (2011) 0.98
Identification of spurious hemolysis in anticoagulated blood with Sysmex XE-2100 and Siemens Advia 2120. Clin Lab (2012) 0.98
Clinical use of Haemate P in inherited von Willebrand's disease: a cohort study on 100 Italian patients. Haematologica (2007) 0.97